JOP20220180A1 - مُعدلات ليباز أُحادِيُّ الجلِيسِريد - Google Patents

مُعدلات ليباز أُحادِيُّ الجلِيسِريد

Info

Publication number
JOP20220180A1
JOP20220180A1 JOP/2022/0180A JOP20220180A JOP20220180A1 JO P20220180 A1 JOP20220180 A1 JO P20220180A1 JO P20220180 A JOP20220180 A JO P20220180A JO P20220180 A1 JOP20220180 A1 JO P20220180A1
Authority
JO
Jordan
Prior art keywords
methods
disorders
monoacylglycerol lipase
modulators
depression
Prior art date
Application number
JOP/2022/0180A
Other languages
English (en)
Inventor
Michael K Ameriks
Brian Ngo Laforteza
Cynthia B Berry
Pablo Garcia-Reynaga
Jimmy T Liang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20220180A1 publication Critical patent/JOP20220180A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

مركبات آزا ثنائي الحلقات 3.1.0 و4.1.0 بالصيغة (I) وتركيبات صيدلانية تحتوي عليها وطرق صنعها، وأساليب استخدامها بما في ذلك وسائل علاج الحالات المرضية والاضطرابات والظروف المرتبطة بتعديل ليباز أحادي الجلِيسِريد (MGL)، مثل تلك المرتبطة بالألم، الاضطرابات النفسية، الاضطرابات العصبية (بما في ذلك، على سبيل المثال لا الحصر، الاضطراب الاكتئابي الرئيسي، والاكتئاب المقاوم للعلاج، والاكتئاب الناتج عن القلق، والاضطراب ثنائي القطب)، والسرطانات وأمراض العيون. ؛ حيث يتم تعريف X، وY، وR1، وR2a، وR2b بهذا الاختراع.
JOP/2022/0180A 2020-02-10 2021-02-09 مُعدلات ليباز أُحادِيُّ الجلِيسِريد JOP20220180A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972484P 2020-02-10 2020-02-10
PCT/EP2021/053062 WO2021160602A1 (en) 2020-02-10 2021-02-09 Monoacylglycerol lipase modulators

Publications (1)

Publication Number Publication Date
JOP20220180A1 true JOP20220180A1 (ar) 2023-01-30

Family

ID=74595268

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0180A JOP20220180A1 (ar) 2020-02-10 2021-02-09 مُعدلات ليباز أُحادِيُّ الجلِيسِريد

Country Status (21)

Country Link
US (2) US11708359B2 (ar)
EP (1) EP4103557A1 (ar)
JP (1) JP2023512729A (ar)
KR (1) KR20220140581A (ar)
CN (1) CN115066422A (ar)
AR (1) AR121296A1 (ar)
AU (1) AU2021220539A1 (ar)
BR (1) BR112022015116A2 (ar)
CA (1) CA3169988A1 (ar)
CL (1) CL2022002136A1 (ar)
CO (1) CO2022011275A2 (ar)
CR (1) CR20220376A (ar)
DO (1) DOP2022000162A (ar)
EC (1) ECSP22062460A (ar)
IL (1) IL295447A (ar)
JO (1) JOP20220180A1 (ar)
MX (1) MX2022009804A (ar)
PE (1) PE20221576A1 (ar)
TW (1) TW202140465A (ar)
UY (1) UY39066A (ar)
WO (1) WO2021160602A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022015116A2 (pt) 2020-02-10 2022-09-27 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipase
BR112022019155A2 (pt) 2020-03-26 2022-12-06 Janssen Pharmaceutica Nv Aril piperidinas como moduladores da monoacilglicerol lipase
CN115335365B (zh) 2020-03-26 2024-06-18 詹森药业有限公司 氨基环丁烷作为单酰基甘油脂肪酶调节剂
AU2021241888A1 (en) 2020-03-26 2022-09-29 Janssen Pharmaceutica Nv Azaspirocycles as monoacylglycerol lipase modulators
CN118076351A (zh) 2021-08-09 2024-05-24 詹森药业有限公司 用于自闭症谱系障碍的单酰基甘油脂肪酶调节剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
KR20140068243A (ko) * 2011-09-30 2014-06-05 얀센 파마슈티카 엔.브이. 대사 질환 및 관련 장애의 치료를 위한 모노아실글리세롤 리파제 억제제
EP3438109B1 (en) 2016-03-31 2021-08-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
MY194647A (en) * 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
EP3689879A4 (en) 2017-09-29 2021-07-14 Takeda Pharmaceutical Company Limited HETEROCYCLIC CONNECTION
WO2020211798A1 (zh) 2019-04-16 2020-10-22 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
BR112022015116A2 (pt) * 2020-02-10 2022-09-27 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipase
BR112022019155A2 (pt) 2020-03-26 2022-12-06 Janssen Pharmaceutica Nv Aril piperidinas como moduladores da monoacilglicerol lipase
CN115335365B (zh) 2020-03-26 2024-06-18 詹森药业有限公司 氨基环丁烷作为单酰基甘油脂肪酶调节剂
AU2021241888A1 (en) 2020-03-26 2022-09-29 Janssen Pharmaceutica Nv Azaspirocycles as monoacylglycerol lipase modulators

Also Published As

Publication number Publication date
EP4103557A1 (en) 2022-12-21
CL2022002136A1 (es) 2023-02-03
DOP2022000162A (es) 2022-10-31
CN115066422A (zh) 2022-09-16
US11708359B2 (en) 2023-07-25
KR20220140581A (ko) 2022-10-18
US20210253565A1 (en) 2021-08-19
AU2021220539A1 (en) 2022-10-06
US20230382902A1 (en) 2023-11-30
CA3169988A1 (en) 2021-08-19
WO2021160602A1 (en) 2021-08-19
CO2022011275A2 (es) 2022-08-30
BR112022015116A2 (pt) 2022-09-27
ECSP22062460A (es) 2022-11-30
CR20220376A (es) 2022-09-16
IL295447A (en) 2022-10-01
MX2022009804A (es) 2022-09-02
UY39066A (es) 2021-08-31
AR121296A1 (es) 2022-05-04
JP2023512729A (ja) 2023-03-28
TW202140465A (zh) 2021-11-01
PE20221576A1 (es) 2022-10-06

Similar Documents

Publication Publication Date Title
JOP20220180A1 (ar) مُعدلات ليباز أُحادِيُّ الجلِيسِريد
PH12021550659A1 (en) Monoacylglycerol lipase modulators
MX2021003661A (es) Moduladores de la monoacilglicerol lipasa.
MX2022011904A (es) Aminociclobutanos como moduladores de monoacilglicerol lipasa.
MX2022011903A (es) Azaspirociclos como moduladores de monoacilglicerol lipasa.
MX2022011901A (es) Arilo piperidinas como moduladores de monoacilglicerol lipasa.
MX2022011902A (es) Moduladores de la monoacilglicerol lipasa.
Harper et al. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes
EA201100461A1 (ru) Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования
KR101210984B1 (ko) 음파를 이용한 중간엽 줄기세포의 신경세포 분화유도 방법
MX366855B (es) Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
MX2012010657A (es) Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
ATE289800T1 (de) Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2023003240A (es) Moduladores de monoacilglicerol lipasa de ciclobutilamida.
EA201992127A1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
MX2023000164A (es) Métodos y composiciones para tratar la hemofilia.
Hagerman et al. Case series: deep brain stimulation in patients with FXTAS
MX2023003165A (es) Moduladores de la caseína cinasa 1 delta.
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.
Zuzic Forward programming of photoreceptors from induced pluripotent stem cells
Borodziuk et al. Stem Cell Therapies for Spinal Cord Injury-A Review
WO2024077043A3 (en) Modifying early-stage parkinson's disease progression with deep brain stimulation